Veliparib (ABT-888)

For research use only.

Catalog No.S1004 Synonyms: NSC 737664

145 publications

Veliparib (ABT-888) Chemical Structure

CAS No. 912444-00-9

Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 156 In stock
USD 120 In stock
USD 227 In stock
USD 370 In stock
USD 617 In stock
USD 990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Veliparib (ABT-888) has been cited by 145 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 NGnlc5FMcW6jc3WgRZN{[Xl? NHHxfpM{OCCvaX6= MoDxTY5pcWKrdHnvckBw\iCSQWLQNUB4cXSqIFXDOVAhd2ZiMD6wNFIh|ryP NFiyeJoyQTh6OEe2NC=>
Jurkat NXT0TphVU2mwYYPlJGF{e2G7 NGfVcJQ6PiCq NY\tUoRZTE2VTx?= NHXrVo1KdmirYnn0bY9vKG:oIGDBVnAyKGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBk\WyuII\pZYJqdGm2eTD3bZRpKEWFNUCgc4YhOyEQvF2= Mk\qNlM5PTBzOUm=
Capan1 M2m5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv5bVllPzJiaB?= M2jadmROW09? MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFLSR2EzKGenbnWgcZV1[XSnZDDoeY1idiCFYYDhclEh[2WubIOge4l1cCCLQ{WwJI9nKDN7Lkeg{txO MWCyOFM6QDN6Mx?=
DT40 NYT3c3ZoS3m2b4TvfIlkKEG|c3H5 NXfFZohSPzJiaB?= NFP5e25FVVOR NUnLUXNvS3m2b4TvfIlkcXS7IHHnZYlve3RiY3jpZ4tmdiCEUlPBNk1l\W[rY3nlcpQhTFR2MDDj[Yxtew>? NHnXXG0zPDl{MkW4Oy=>
ML-1 MWjBdI9xfG:2aXOgRZN{[Xl? MnPNNk42KM7:TR?= MnfCNlQhcA>? NXrwd5VyTE2VTx?= MX3TfY5memerc4TpZ4FtdHliZX7oZY5k\XNiVGLBTWwucW6mdXPl[EBieG:ydH;zbZMhcW5iTVytNUBk\Wyucx?= NEHNc5MzPDh7NUGzOS=>
HCT-116 M1v2d2tqdmG|ZTDBd5NigQ>? M1;BRlAvPSEQvF2= NHLDdnEzPCCq Ml7TVGFTWCCjY4Tpeol1gSCmZXPy[YF{\XN? NIP1RVgzOzB3NEKxNy=>
UM-SCC1 M4DjWWN6fG:2b4jpZ{BCe3OjeR?= NF\YV4QyOCEQvF2= NUjFWXptOjRiaB?= M2O5VHJm\HWlZYOgeIhmKGOnbHygeoli[mmuaYT5 NEjMR2UzOTlzMk[yNC=>
FaDu NFnYUI5EgXSxdH;4bYMhSXO|YYm= MoO1NVAh|ryP MmTRNlQhcA>? MWDS[YR2[2W|IITo[UBk\WyuII\pZYJqdGm2eR?= MY[yNVkyOjZ{MB?=
PC-3 NEH5T3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDrflUyOCEQvF2= MXXJcoR2[2W|IHGgd4lodmmoaXPhcpQhcW6qaXLpeIlwdiCrbjDjc4xwdnliZn;ycYF1cW:wwrC= NVXJXIRROjF3N{G5NVI>
EoL-1-cell NHjEXlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXQV2VKSzVyPUGuNFc6QCEQvF2= Mm[yV2FPT0WU
NCI-SNU-5 NYrvTJhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\DS2lEPTB;Mz6xNlg1OSEQvF2= NV32cGFRW0GQR1XS
BV-173 NUS5ZpVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXtTWM2OD13LkS1OFA6KM7:TR?= NHnjfpFUSU6JRWK=
HCC1806 MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfJeVh2UUN3ME21Mlc2OTd|IN88US=> M17ZeHNCVkeHUh?=
COLO-680 NVO3Z3RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\ETWM2OD14LkKxOFA3KM7:TR?= NVnmW3lbW0GQR1XS
HCC2218 MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmSwTWM2OD15Lke5O|A1KM7:TR?= NWK0UIhkW0GQR1XS
SK-MEL-24 NGLBcmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEC4b5RKSzVyPUeuPFE6OjRizszN M{XRc3NCVkeHUh?=
NCI-H720 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLGOIJKSzVyPUiuOFM3ODNizszN M165fHNCVkeHUh?=
KASUMI-1 Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjYdodKSzVyPUiuPFkzPjZizszN M3[4R3NCVkeHUh?=
HAL-01 NVeyVnpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTlwOEi2NkDPxE1? NHy2N|BUSU6JRWK=
CAL-33 NHrsZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFyLkSzOEDPxE1? Ml;uV2FPT0WU
SK-MEL-1 NET6[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF{LkS2OlMh|ryP MWXTRW5ITVJ?
Ramos-2G6-4C10 M1L0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjlTmZKSzVyPUGyMlQ4PTJizszN M1n0RXNCVkeHUh?=
KY821 MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrJcoVuUUN3ME2xNk41QDVizszN Mlj0V2FPT0WU
HEC-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEizbIxKSzVyPUGyMlkyQTZizszN NET3PFlUSU6JRWK=
SK-NEP-1 NGLRWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS2emJKSzVyPUGzMlE3PiEQvF2= NHOzUIpUSU6JRWK=
MN-60 MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF|LkWzPFkh|ryP MmP6V2FPT0WU
DU-145 NXnGU3E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjzTWM2OD1zMz65NFU{KM7:TR?= NV;UZ5dbW0GQR1XS
EW-3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF2LkW1OlUh|ryP NYrsPItuW0GQR1XS
OS-RC-2 M2XaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHjWXRKSzVyPUG1Mlk2QDlizszN MU\TRW5ITVJ?
RPMI-8226 MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\tTWM2OD1zNj6yNFQzKM7:TR?= M4r5fHNCVkeHUh?=
ChaGo-K-1 NEnsTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrxTWM2OD1zNj61N|I2KM7:TR?= NVvPPZNQW0GQR1XS
DEL MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37jXmlEPTB;MU[uOlcyPyEQvF2= M1nTZ3NCVkeHUh?=
GP5d MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf3WWJKSzVyPUG3MlA2OyEQvF2= NU\YT3hXW0GQR1XS
COLO-668 M4i0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzyTWM2OD1zNz62Nlk1KM7:TR?= NVnjUHFxW0GQR1XS
H9 MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X0U2lEPTB;MUiuNlg{OyEQvF2= M4HTWnNCVkeHUh?=
NKM-1 M3O5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[1NHljUUN3ME2xPE42OTF7IN88US=> MnH6V2FPT0WU
KYSE-150 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorOTWM2OD1zOD65PVg3KM7:TR?= M3fNbXNCVkeHUh?=
Daoy MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfHV49DUUN3ME2xPU42PjR7IN88US=> NE\q[WdUSU6JRWK=
ECC10 NXvEXYtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnUSIpQUUN3ME2yNE44PDV3IN88US=> MUDTRW5ITVJ?
A388 MknvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n4bGlEPTB;MkGuPVA6OSEQvF2= MlSyV2FPT0WU
MHH-NB-11 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfQVm03UUN3ME2yN{4yOzZ|IN88US=> MWfTRW5ITVJ?
HCC1937 NI\rNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHOU2l[UUN3ME2yOE44PDZizszN MXrTRW5ITVJ?
TGBC11TKB NVHJUHhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\XcotKSzVyPUK1MlY5PjNizszN NWTOR|BCW0GQR1XS
CTV-1 MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorKTWM2OD1{NT64PVY6KM7:TR?= NI\ZV2tUSU6JRWK=
NCI-H2029 NHrXSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XDcWlEPTB;Mk[uOFI{QCEQvF2= MWHTRW5ITVJ?
HLE NXrCdFZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Sxb2lEPTB;MkeuNFU1KM7:TR?= M1zkO3NCVkeHUh?=
NCI-H1693 NV;Eflc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzVco5KSzVyPUK3MlI5QThizszN NHrJSHpUSU6JRWK=
HCC70 MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\QZ3p5UUN3ME2yO{44OjR4IN88US=> M{\aRXNCVkeHUh?=
BEN NHLkWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\LcI5nUUN3ME2yO{46PTZ4IN88US=> MVPTRW5ITVJ?
LB771 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LubGlEPTB;MkiuPFM4OyEQvF2= M4r3SnNCVkeHUh?=
697 MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPtTWM2OD1{OT6wNlM2KM7:TR?= M1vaNnNCVkeHUh?=
LU-139 MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ7LkO3OFgh|ryP NFvNbWhUSU6JRWK=
EW-13 NV;PXXgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLXTWM2OD1{OT6zPFE1KM7:TR?= MYrTRW5ITVJ?
MOLT-13 MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJ7LkO4NVQh|ryP NVvjUpR1W0GQR1XS
L-363 M1[5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jSSGlEPTB;MkmuOFc6QCEQvF2= NWHHVG9pW0GQR1XS
EM-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknLTWM2OD1{OT60PVAyKM7:TR?= MUHTRW5ITVJ?
RS4-11 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnmXJVyUUN3ME2zNE41OjRzIN88US=> Mmn2V2FPT0WU
A2780 NWTqO2Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PYeGlEPTB;M{CuO|Q2PyEQvF2= NF7VbFFUSU6JRWK=
KU812 NXzoZng1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPiSIxKSzVyPUOyMlM3PDJizszN NGT2TWtUSU6JRWK=
COLO-684 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTN|LkO1PVkh|ryP M3Xqe3NCVkeHUh?=
MFE-280 NYf6OFR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;IT3hKSzVyPUOzMlM5QDlizszN NGHGUYNUSU6JRWK=
KG-1 M2PLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTN|Lk[wNFEh|ryP MlzQV2FPT0WU
JVM-3 NHvhRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTN3LkW4Olgh|ryP MWLTRW5ITVJ?
MV-4-11 NVLSdVRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTN3Lki0PVkh|ryP Mo\nV2FPT0WU
LAMA-84 MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTN4LkezOFUh|ryP NGDqUIpUSU6JRWK=
MOLT-16 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofTTWM2OD1|Nj65OVIh|ryP NXHFV3VuW0GQR1XS
H4 NEXLWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX3OHpKSzVyPUO3MlU3PyEQvF2= NGTafotUSU6JRWK=
T47D MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTN5LkewNVgh|ryP NXu4[3JqW0GQR1XS
CAL-54 NFPrfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[0[IJMUUN3ME2zO{46PjZizszN MYHTRW5ITVJ?
SW982 NX\TfJZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXuTWM2OD1|OD6wPVk5KM7:TR?= NWDq[FlIW0GQR1XS
IGROV-1 NIPjZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT4XGlOUUN3ME2zPU4{OzB2IN88US=> NED1cWRUSU6JRWK=
NB14 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv6N4ZoUUN3ME20NE44ODNzIN88US=> MkPvV2FPT0WU
HCC1187 NX:1PIdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHRbohKSzVyPUSxMlI4PzFizszN MVLTRW5ITVJ?
SBC-1 NHS4ZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTRzLkOwOlMh|ryP NETBcYhUSU6JRWK=
KARPAS-45 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TvUWlEPTB;NEGuOFgyQCEQvF2= NFHHVIdUSU6JRWK=
MOLT-4 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:1N4s2UUN3ME20Nk4zPTN6IN88US=> NVvhTWV[W0GQR1XS
JVM-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTR{LkmyNFch|ryP MY\TRW5ITVJ?
A4-Fuk MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPzWlFKSzVyPUSzMlU3QTFizszN NI\a[|dUSU6JRWK=
MDA-MB-361 NUX0fmxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\ofmlEPTB;NEOuPFQyPCEQvF2= NHT2bHRUSU6JRWK=
BALL-1 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTR|Lkm1N|Ih|ryP MlLhV2FPT0WU
T98G MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILNPWJKSzVyPUS0Mlg2OTdizszN NXnl[o1mW0GQR1XS
Mo-T MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzLTWM2OD12NT62N|g6KM7:TR?= MYLTRW5ITVJ?
MHH-PREB-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LVW2lEPTB;NEWuO|U5PSEQvF2= NFOxTWJUSU6JRWK=
ALL-PO MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofqTWM2OD12Nz6zO|kyKM7:TR?= NWf0T3NSW0GQR1XS
NCI-H510A M1PqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm0TWM2OD12Nz65NFM1KM7:TR?= M{jmSHNCVkeHUh?=
ML-2 NYTxNlFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPDV4V{UUN3ME20PU44QDV4IN88US=> NHvObItUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-STAT3 / STAT3 / p-AKT(S473) / p-AKT(T308) / p-ERK / p-p38; 

PubMed: 22678161     


Effects of AG-014699, AZD-2281, ABT-888, or BSI-201 on the phosphorylation status of Stat3, Akt, ERK, and p38 in MDA-MB-468, MDA-MB-231, and Cal-51 cells after 72 h of treatment

22678161
Immunofluorescence
HuR; 

PubMed: 28687616     


Immunofluorescent images of HuR (green) in MIA PaCa-2 cells treated with PARPi for 12hr. Nuclei were stained with DAPI. Magnification 40X.

BRCA1; 

PubMed: 21917757     


Effects of ABT-888 and/or bortezomib on BRCA1 and RAD51 foci formation. BRCA1 and RAD1 foci induced by ABT-888 were completely resolved in cells cotreated with bortezomib. Image acquisition was performed with an epifluorescence microscope (BX51; Olympus) and multispectral color camera (Nuance FX; CRi) with a 60× or 100× magnification lens and oil immersion.

28687616 21917757
Growth inhibition assay
Cell viability (TNBC cell lines); 

PubMed: 27880910     


BRCA-proficient TNBC cell lines were treated with veliparib in the absence and presence of dinaciclib, demonstrating reduced IC50 values in the presence of dinaciclib.

Cell viability (melanoma cells); 

PubMed: 29956724     


Dose-dependent inhibitory effect of ABT-888 on melanoma cell proliferation. Human melanoma cell lines were exposed to diluents (control; CTRL) or increasing concentrations of ABT-888 for 72 h and their viability was assessed by MTT assay. Absorbance was detected at 540 nm with a microplate reader and data were expressed as a percentage of the CTRL. Data are the means ± SD of 3 experiments performed in triplicate. Statistical significance was calculated against the CTRL (*P<0.05; **P<0.01).

27880910 29956724
In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

Protocol

Animal Research:

[1]

- Collapse
  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Dosages: ~25 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% methylcellulose+0.2% Tween 80
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.29
Formula

C13H16N4O

CAS No. 912444-00-9
Storage powder
in solvent
Synonyms NSC 737664
Smiles CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03044795 Withdrawn Drug: Veliparib Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2019 Phase 2
NCT02723864 Active not recruiting Drug: Veliparib + VX-970 + Cisplatin Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2017 Phase 1
NCT02483104 Completed Drug: veliparib|Drug: carboplatin|Drug: paclitaxel Ovarian Cancer AbbVie July 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Veliparib (ABT-888) | Veliparib (ABT-888) supplier | purchase Veliparib (ABT-888) | Veliparib (ABT-888) cost | Veliparib (ABT-888) manufacturer | order Veliparib (ABT-888) | Veliparib (ABT-888) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID